Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L- proline and L-isoleucyl-L-prolyl-L-proline): II. Introduction

International Journal of Toxicology

Volumn 24, Issue SUPPL. 4, 2005, Pages 5-11

  Bernard, Bruce K ^a   Nakamura, Yasunori ^b   Bando, Izuki ^b   Mennear, John H ^c  

^a GENERAL DYNAMICS   (United States)

^b CALPIS Co Ltd   (Japan)

^c CAMPBELL UNIVERSITY   (United States)

Author keywords

Food Ingredient; Generally Recognized as Safe (GRAS); IPP; Normotensive Effects; Tripeptides; VPP

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOOD ADDITIVE; ISOLEUCYLPROLYLPROLINE; TRIPEPTIDE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD CHEMISTRY; CHEMICAL STRUCTURE; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; ENZYME INHIBITION; FERMENTED PRODUCT; HUMAN; JAPAN; MILK; NONHUMAN; PULSE RATE; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 27544480832     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810500259531     Document Type: Review

References (32)

1. Bernard, B. K., Y. Nakamura, K. Aihara, and J. H. Mennear. 2005. Studies of the lexicological potential of tripeptides (L-valy-L-prolyl-L-proline and L-isoleucyl-L-proplyl-L-proline): IX. Evaluation of the mutagentic potential of synthesized L-valyl-L-prolyl-L-proline in the Salmonella-Esherichia coli/microsome incorporation assay. Int. J. Toxicol. 24(Suppl. 4):107-113.
2. Calpis Co., Ltd.: http://www.calpis.co.jp/images/000001200.pdf [In Japanese]
3. Hata, Y., M. Yamamoto, M. Ohni, K. Kanajima, Y. Nakamura, and T. Takano. 1996. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J. Clin. Nutr. 64:767-771.
4. Hirata, H., Y. Nakamura, H. Yada, S. Moriguchi, O. Kajimoto, and T. Takahashi. 2002. Clinical effects of new sour milk drink in mild or moderate hypertensive subjects. [In Japanese, English abstract.] J. New Rem. Clin. 51:60-69.
5. Itakura, H., S. Ikemoto, S. Terada, and K. Kondo. 2001. The effect of sour milk on blood pressure in untreated of hypertensive and normotensive subjects. J. Jpn. Soc. Clin. Nutr. 23:26-31.
6. Kajimoto, O., K. Aihara, H. Hirata, R. Takahashi, and Y. Nakamura. 2001a. Safety evaluation of excessive intake of the tablet containing "lactotripeptides (VPP, IPP)" in healthy volunteers. [In Japanese, English abstract.] J. Nutr. Food 4:37-46.
7. Kajimoto, O., K. Aihara, H. Hirata, R. Takahashi, and Y. Nakamura. 2001b. Hypotensive effects of the tablets containing "lactotripeptides (VPP, IPP)." [In Japanese, English abstract] J. Nutr Food 4:51-61.
8. Kajimoto, O., T. Kurosaki, J. Mizutani, N. Ikeda, K. Kaneko, M. Yabune, and Y. Nakamura. 2002. Antihypertensive effects of the liquid yogurt containing "lactotripeptides (VPP, IPP)" in mild hypertensive subjects. [In Japanese, English abstract.] J. Nutr. Food 5:55-66.
9. Kajimoto, O., Y. Nakamura, H. Yada, S. Moriguchi, H. Hirata, and T. Takahashi. 2001c. Hypotensive effects of sour milk in subjects with mild or moderate hypotension. [In Japanese, English abstract.] J. Jap. Soc. Nutr. Food Sci. 54:347-354.
10. Kurosaki, T., M. Maeno, J. H. Mennear, and B. K. Bernard. 2005. Studies of the toxicological potential of tripeptides (L-valyl-L-proplyl-L-proline and L-isoleucyl-L-prolyl-L-proline): VI. Effects of Lactobacillus helveticus-fermented milk powder on fertility and reproductive performance of rats. Int. J. Toxicol. 24(Suppl. 4):61-89.
11. Maeno, M., S. Mizuno, J. H. Mennear, and B. K. Bernard. 2005a. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): VIII. Assessment of cytotoxity and clastogenicity of tripeptides-containing casein hydrolysate and Lactobacillus helveticus-fermented milk powders in Chinese hamster lung cells. Int. J. Toxicol. 24(Suppl. 4):97-105.
12. Maeno, M., Y. Nakamura, J. H. Mennear, and B. K. Bernard. 2005b. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): III. Single- and/or repeated-dose toxicity of tripeptides-containing Lactobacillus helveticus-fermented milk powder and casein hydrolysate in rats. Int. J. Toxicol. 24(Suppl. 4):13-23.
13. Masuda, O., Y. Nakamura, K. Sakai, and T. Takano. 1995. Presence of VPP and IPP peptides in various fermented milks. Unpublished report, Calpis Research Development Center.
14. Masuda, O., Y. Nakamura, T. Takano, 1995. Description of an electodialyzed Calpis sour milk and its anti-hypertensive effect on spontaneous hypertensive rats. Unpublished report, Calpis Research Development Center.
15. Matsuura, K., J. H. Mennear, M. Maeno, and B. K. Bernard. 2005. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): VII. Micronucleus test of tripeptides- containing casein hydrolysate and Lactobacillus helveticus-fermented milk powders in rats and mice. Int. J. Toxicol. 24(Suppl. 4):91-96.
16. Mizuno, S., K. Matsuura, T. Gotou, S. Nishimura, O. Kajimoto, M. Yabune, Y. Kajimoto, N. Yamamoto. 2005a. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild-hypertension. Br. J. Nutr. 93:1-9.
17. Mizuno, S., J. H. Mennear, K. Matsuura, and B. K. Bernard. 2005b. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): V. A 13-week toxicity study of tripeptides-containing casein hydrolysate in male and female rats. Int. J. Toxicol. 24(Suppl. 4):41-59.
18. Mizushima, S., K. Ohshige, J. Watanabe, M. Kimura, T. Kadowaki, Y. Nakamura, O. Tochikubo, and H. Ueshima. 2004. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am. J. Hypertens, 17:701-706.
19. Nakamura, Y., I. Bando, J. H. Mennear, and B. K. Bernard. 2005. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-Lprolyl-Lproline): IV. Assessment of the repeated-dose toxicological potential of synthesized L-valyl-L-prolyl-L-proline in male and female rats and dogs. Int. J. Toxicol. 24(Suppl. 4):25-39.
20. Nakamura, Y., O. Kajimoto, K. Kaneko, K. Aihara, J. Mizitani, N. Ikeda, A. Nishimura, and Y. Kajimoto. 2004. Effects of the liquid yogurts containing "lactotripeptide (VPP, IPP)" on high-normal blood pressure. [In Japanese, English abstract.] J. Nutr. Food 7:123-137.
21. Nakamura Y., O. Masuda, and T. Takano. 1996. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci. Biotechnol. Biochem. 60:488-489.
22. Nakamura Y., N. Yamamoto, K. Sakai, S. Okubo, S. Yamasaki, and T. Takano. 1995a. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci. 78:777-783.
23. Nakamura Y., N. Yamamoto, K. Sakai, and T. Takano. 1995b. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci. 78:1253-1257.
24. Ondetti, M. A., B. Rubin, and D. W. Cushman. 1977. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 196:441-444.
25. Seppo, L., T. Jauhiainen, T. Poussa, and R. Korpela. 2003. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am. J. Clin. Nutr., 77:326-330.
26. Seppo, L., O. Kerojoki, T. Suomalainen, and R. Korpela. 2002. The effect of a Lactobacillus helveticus LBK-16 H fermented milk on hypertension-a pilot study on humans. Milchwissenschaft 57:124-127.
27. Tuomilehto, J., J. Lindstrom, J. Hyyrynen, R. Korpela, M.-L. Karhunen, L. Mikkola, T. Jauhiainen, L. Seppo, and A. Nissinen. 2004. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J. Hum. Hypertens. 18:795-802.
28. U.S. Department of Agriculture (USDA) Agricultural Research Service. 1998. Data tables: Results from USDA's 1994-96 continuing survey of food intakes by individuals. NTIS PB98-500457. Washington, DC: U.S. Dept. Commerce.
29. Yamamoto, N., A. Akino, and T. Takano. 1994a. Antihypertensive effect of the peptides derived from casein by an extracellular proteinase derived from Lactobacillus helveticus CP790. J. Dairy Sci. 77:917-922.
30. Yamamoto, N., A. Akino, and T. Takano. 1994b. Antihypertensive effects of different kinds of fermented milk in spontaneously hypertensive rats. Biosci. Biotechnol. Biochem. 58:776-778.
31. Yamamoto, N., H. Kawakami, Y. Ishida, and H. Yada. 1999. Screening of lactotripeptides producing lactobacilli, Lactobacillus helveticus. unpublished report, Calpis Research Development Center.
32. Yasuda, K., K. Aihara, K. Komazaki, M. Mochii, and Y. Nakamura. 2001. Effect of large intake of tablets containing "lactotripeptides (VPP, IPP)" on blood pressure, pulse rate and clinical parameters in healthy volunteers. [In Japanese, English abstract.] J. Nutr. Food 4:63-72.